| Name | Title | Contact Details |
|---|
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aviva Labs Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.